This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Psoriasis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

Catherine H. Smith, MD, FRCP; Anthony D. Ormerod, FRCP

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We are pleased that the British Association of Dermatologists guidelines on use of biological therapies in psoriasis¹ have been highlighted and summarized so succinctly. We are also glad that the reviewing author, Dr Nijsten,² found them to be "clear and informative" and that he recommends their use. However, we are concerned that his conclusion (as stated in the abstract and in the commentary) that "etanercept is the biological drug of choice in most eligible patients with stable disease with or without psoriatic arthritis" is a misrepresentation of what is stated in the guidelines. Indeed, we were very careful not to provide explicit guidance as to which of the agents covered (etanercept, infliximab, and efalizumab) should be the preferred choice given the lack of evidence available at the time.

The specific recommendations in the guidelines in relation to etanercept are as follows¹. . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Level of Agreement With the British Guidelines for the Use of Biological Therapies for Psoriasis
Tamar Nijsten
Arch Dermatol. 2007;143(12):1567-1569.
EXTRACT | FULL TEXT